Leukemia Sel Plasma Primer
DOI:
https://doi.org/10.21776/ub.jkb.2017.029.03.17Keywords:
Leukemia sel plasma, mieloma multipel, sel plasmaAbstract
Leukemia sel plasma merupakan penyakit yang langka, hanya sekitar 2-4% dari plasma cell dyscrasia. Manifestasi klinis leukemia sel plasma primer lebih agresif dibandingkan dengan mieloma multipel. Artikel melaporkan kasus pasien laki-laki berumur 59 tahun datang ke Instalasi Gawat Darurat (IGD) dengan keluhan badan lemah dan nyeri pada kedua kaki sejak sebulan yang lalu dan memberat seminggu terakhir. Pasien juga mengeluhkan nyeri punggung, mual, penurunan nafsu makan, dan penurunan berat badan. Pemeriksaan fisik menunjukkan penurunan respon motorik pada ekstrimitas bawah. Pemeriksaan laboratorium menunjukkan anemia normokrom normositik, leukositosis dengan 60% sel plasma, trombositopenia, hipoglobulinemia, azotemia, hiperkalsemia, hiperfosfatemia, hiponatremia, hipogamaglobulinemia pada elektroforesis protein, dan 50% sel plasma pada aspirasi sumsum tulang. Bone survey menunjukkan proses metastasis pada tulang. Diagnosis leukemia sel plasma primer ditegakkan oleh adanya lebih dari 20% sel plasma atau jumlah absolut sel plasma lebih dari 2x109/l pada darah tepi, tidak ada riwayat mieloma multipel, dan gambaran klinis yang agresif.
Kata Kunci: Leukemia sel plasma, mieloma multipel, sel plasma
Downloads
References
Fernández de Larrea C, Kyle RA, Durie BG, et al. Plasma Cell Leukemia: Consensus Statement on Diagnostic Requirements, Response Criteria and Treatment Recommendations by the International Myeloma Working Group. Leukemia. 2013; 27(4): 780-791
Dispenzieri A, Lacy MQ, and Greipp PR. Multiple Mieloma. In: Greer JP, Foerster J, Rodgers GM, et al (Eds). Wintrobe's Clinical Hematology 12th Edition. Philadelphia-USA: Lippincott Williams & Wilkins. 2009: 2414-2415.
Albarracin F and Fonseca R. Plasma Cell Leukemia. Blood Reviews. 2011; 25(3): 107-112.
Chokshi MH, Baji SN, and Gandhi AS. Plasma Cell Leukemia: A Comprehensive Analysis of Clinical
& Pathological Features of 7 Cases. International Journal of Medical Science and Public Health. 2014; 3(1): 6-9.
Lebovic D, Zhang L, Alsina M, et al. Clinical Outcomes of Patients with Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single Institution Experience. Clinical Lymphoma, Myeloma, and Leukemia. 2011; 11(6): 507-511.
Fonseca D, Ahmed F, Murthy S, and Rajappa S. Plasma Cell Leukemia, Case Report. International Journal of Pharma and Bio Sciences. 2012; 3(3): 476-481.
van de Donk NWCJ, Lokhorst HM, Anderson KC, and Richardson PG. How I Treat Plasma Cell Leukemia. Blood. 2012; 120(12): 2376-2389.
Kraj M, Kopeć-Szlęzak J, Pogłód R, and Kruk B. Flow Cytometric Immunophenotypic Characteristics of 36 Cases of Plasma Cell Leukemia. Leukemia Research. 2011; 35(2): 169-176.
Johnson MR, Del Carpio-Jayo D, Lin P, et al. Primary Plasma Cell Leukemia: Morphologic, Immunophenotypic, and Cytogenetic Features of 4 Cases Treated with Chemotherapy and Stem Cell Transplantation. Annals of Diagnostic Pathology. 2006; 10(5): 263–268.
Kumar S, Kimlinger T, and Morice W. Immunophenotyping in Multiple Myeloma and Related Plasma Cell Disorders. Best Practice & Research. Clinical Haematology. 2010; 23(3): 433–451.
Dimopoulos MA, Kastritis E, Rosinol L, Blade J and Ludwig H. Pathogenesis and Treatment of Renal Failure in Multiple Myeloma. Leukemia. 2008; 22(8): 1485–1493.
Heher EC, Rennke HG, Laubach JP, and Richardson PG. Kidney Disease and Multiple Myeloma. Clinical Journal of the American Society of Nephrology. 2013; 8(11): 2007-2017.
Oyajobi BO. Multiple Myeloma/Hypercalcemia: Review. Arthritis Research & Therapy. 2007; 9(Suppl 1): S4.
Dadu T, Rangan A, Handoo A, and Bhargava M. Primary Non-Secretory Plasma Cell Leukemia with Atypical Morphology-A Case Report. Indian Journal of Hematology and Blood Transfusion. 2009; 25(2): 81–83
Giuliani N, Colla S, and Rizzoli V. Update on the Pathogenesis of Osteolysis in Multiple Mieloma Patients. Acta Bio-Medica: Atenei Parmensis. 2004; 75(3): 143-152.
Giuliani N, Rizzoli V, and Roodman GD. Multiple Myeloma Bone Disease: Pathophysiology of Osteoblast Inhibition. Blood. 2006; 108(13): 3992-3996.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).